Cochlear Ltd (ASX: COH) Share Price and News

Ms McLoughlin is chair and non-executive director with more than 15 years' experience on the boards of ASX Top 50 Companies in financial services, resources, health insurance and infrastructure sectors. As well as 25 years in financial services and telecommunications leadership positions, Christine brings expertise in corporate governance, strategic and digital transformation and stakeholder leadership. During her tenure as experience of Suncorp, she led strategic transformations in the Australian financial services sector, overseeing long-term strategy, consolidation actions, capital allocation, governance and shareholder value creation. As Chairman of Aware Super, she brings further experience in stewardship and investment oversight, gained from overseeing a regulated sector. She has been active in the not-for profit sector over her entire career. Other boardsinclude Chairman Aware Supe, Member of the Australian Government's Takeover Panel and Chair and Co-founder of the Minerva Network. She was Chairman and Director of Suncorp Group Limited. Director, nib Holding Limited, Whitehaven Coal Limited and Spark Infrastructure, The Chancellor of the University of Wollongong and Chairman and Director of Venues NSW and Chairman of Destination NSW. She is member of Risk Committee, Product and Services Innovation Committee and chair of People and Culture Committee.

Sir Daniell is in medical device industry with more than 40 years' experience across healthcare, engineering, research and development, product innovation and commercialisation. Michael has experience in developing and scaling medical technologies and leading global healthcare businesses in regulated international markets. Michael was Managing Director and Chief Executive Officer from 2001 to 2016 at Fisher & Paykel Healthcare Corporation Ltd. During his tenure, he led the company's global strategy and operations, including the research, design, development, manufacture and commercialisation of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. Other boards include Director, Fisher & Paykel Healthcare Corporation Ltd. Director, Tait International Limited. Director, Medical Research Commercialisation Fund and Former directorships include Advisory Board Chair, Te Titoki Mataora (NZ). He is Member of Risk Committee, Medical Science Committee and chair of Product and Services Innovation Committee.

Ms Deans is experienced non-executive director and former chief executive with more than 30 years' experience leading and governing technology-enabled businesses across e-commerce, media and financial services in Australia and internationally. She is Former Chief Executive Officer of Netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand and has record of leading digital transformation and growth and experience overseeing technology strategy, capital allocation, risk management and financial performance through her ASX-listed board roles. Her board experience spans regulated industries including healthcare, financial services and advanced technology, providing governance capability across strategic planning, cyber and technology oversight, digital innovation, transformation, remuneration and risk management. Through her leadership of global businesses, Alison also brings international commercial perspective and insight into evolving customer expectations and emerging technologies. Other boards: Director, Ramsay Health Care Limited and Fitness Passport Pty Ltd; Chair of Calix Limited; Director of The Observership Program. Former directorships include SCEGGS Darlinghurst Limited, Westpac Banking Corporation, Insurance Australia Group Limited, Deputy Group Pty Ltd and Social Ventures Australia. She is Former Member of AICD Corporate Governance Committee.

Ms Penrose is non-executive director since 2014, serving on the boards of a number of ASX100 companies across multiple industries, including health, property and financial services. Karen is an experienced audit and risk committee chair and chair of due diligence committees for mergers and acquisitions and capital raisings, with experience in financial management, enterprise risk, internal controls, sustainability and technology transformation. In addition, she currently chairs a people and culture committee, contributing board-level oversight of organisational culture and remuneration. Karen has had an executive career in senior leadership and Chief Financial Officer (CFO) roles. This includes 20 years in banking with CBA and HSBC, and eight years as a listed company CFO. These roles have provided experience in capital allocation, corporate strategy, and navigating regulatory environments. Other boards include Director, Ramsay Health Care Limited; Bank of Queensland Limited and Charter Hall Group; Director of Ramsay General De Sante (associated with directorship of Ramsay Health Care Limited) and Marshall Investments Pty Limited. She also serves in a voluntary capacity as a Director on Golf Australia's risk and audit committee. She is chair of risk committee and member of People and Culture Committee, Product and Services Innovation Committee. She is member of People and Culture Committee, Product and Services Innovation Committee and chair of Risk Committee.

Mr Freudenstein is executive and non-executive director in technology, digital transformation, strategy and corporate governance, Richard brings great experience leading and managing businesses operating in regulated industries. Richard has held senior executive leadership roles across Australia's leading media and digital businesses, including as CEO of The Australian and News Digital Media at News Ltd, and CEO & Managing Director of Foxtel. During his tenure in these roles, he led the transformation of traditional media businesses into digitally enabled, customer-focused organisations. This experience has given him a background in operating regulated businesses, developing growth strategies and leading businesses through transformation. Other boards: Non-executive Director, REA Group Limited and Coles Group Limited. Board member, Cricket Australia. Former directorships include Director, Ten Network Holdings Ltd and Astro Malaysia Holdings Berhad. Chair, Appen Limited. Deputy Chancellor, University of Sydney. He is member of People and Culture Committee, Product and Services Innovation Committee.

Mr Robinson has over 35 years' leadership experience in clinical medicine, research and development (R&D), healthcare strategy, leading multidisciplinary research teams and the translation of scientific innovation into improved patient outcomes. His experience spans the full innovation pathway, from fundamental scientific research and clinical investigation through to commercialisation and healthcare implementation. His R&D leadership extends to the corporate sector as Chair of Mayne Pharma Group Limited and its Science, Technology and Medical Committee, overseeing R&D and innovation across the company's pharmaceutical portfolio. He holds a number of senior academic, clinical and research leadership positions, including Co Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research and Chair of Research, North Sydney Local Health District. He was the former Dean of The University of Sydney's Sydney Medical School and Head of Medicine at Sydney's Royal North Shore Hospital. Other boards include Chair of Mayne Pharma Group Limited, Director of Healius Limited and CS Pharmaceuticals Limite; Council Member of Hoc Mai Foundation; Advisor to MinterEllison. Former directorships include Chairman, National Health and Medical Research Council and Medical Benefits Schedule Review Taskforce; Director, Woolcock Institute of Medical Research, Qbiotics Group Limited and Ecofibre Limited. He is member of Risk Committee, Product and Services Innovation Committee and chair of Medical Science Committee.

Mr Howitt held a range of senior leadership roles across the Company including Chief Operating Officer, President, Asia Pacific and SVP, Manufacturing and Logistics. This background underpins strategic capability, built through executive leadership across Cochlear's global operations and multi regional teams. Prior to joining Cochlear, Dig worked for Boston Consulting Group and held a General Management role at Boral.

Mr Prado has more than 38 years' experience in the medical device and pharmaceutical industries. He brings experience in global strategy, healthcare innovation, commercialisation, international operations and organisational leadership, developed through senior executive roles across global markets. He held executive leadership positions with Johnson & Johnson across its medical device businesses in the US and served as Group Chairman of Ethicon, a global leader in medical devices and technologies focused on advancing surgical technologies and improving patient outcomes. Throughout his executive career, he was responsible for developing and executing global strategy, driving innovation and commercialisation. His international experience provides insight into global healthcare systems, evolving market dynamics, regulatory environments and strategic partnerships. Other boards incldue Director, Ambu A/S and a Member of the Board of Trustees of Franciscan University, Steubenville, Ohio. He was Co-lead Director, Verb Surgical. Advisory Board, Singapore Management University Lee Kong Chian School of Business. He is member of Medical Science Committee, People and Culture Committee, Product and Services Innovation Committee.

Ms Clarke has over 20 years of executive leadership roles in healthcare and consumer technology and services, leading global businesses and multi-country teams. Caroline has experience in and brings an international perspective to global strategy, commercial leadership, innovation and governance. Caroline spent more than two decades with Philips, including serving as Executive Vice President of global Consumer and Health Care businesses responsible for global strategy and innovation development and delivery. She led the overall Consumer and Health Care businesses across ASEAN Pacific and was responsible for businesses across 14 countries in the region, overseeing a portfolio of medical technologies, healthcare solutions and consumer health products. Her international leadership experience provides insight into global healthcare systems, changing patient and customer expectations and regulatory environments. Former directorships include Director, Royal Schiphol Group. She is member of People and Culture Committee, Product and Services Innovation Committee.

-

-

-

-

-

-